|
Imaging features of intestinal metastasis from pulmonary sarcomatoid carcinoma
|
H. Wu   , T. Tang , L.B. Yi |
| Department of Oncology, Department of General Surgery, The People's Hospital of Shifang, Sichuan, China , 937089375@qq.com |
|
|
Abstract: (851 Views) |
Background: The aim of this study was to examine the imaging features of patients diagnosed with pulmonary sarcoma (PSC) exhibiting small bowel metastases, utilizing magnetic resonance imaging (MRI) and computed tomography (CT), and to report the clinical outcomes of surgical resection in conjunction with duvacizumab drug therapy. Materials and Methods: Clinical data and CT imaging markers of patients with pathologically confirmed primary pulmonary sarcoma from January 2020 to April 2021 were retrospectively assessed. Results: Immunohistochemical analysis of lung tissue samples indicated Galectin-3(+), PAS(-), Myoglobin(-), F8(-), CD31(-), TTF(+), P40(-), D2-40(-), HMB45(-), AE1/AE3(+), MC(-), and CD68(-). PD-L1 positive cell count, as determined through immunohistochemical evaluation, was 50%. Immunohistochemical findings of the patient's small intestine tissue revealed AE1/AE3(+), CD117(-), CD34(-), Desmin(-), SMA(-), Vimentin(+), S-100(-), CK7(-), CK20(-), CEA(-), EMA(-), PAS(-), CD45(-), with a Ki-67 positivity rate of approximately 40%. Following 11 cycles of duvacizumab drug therapy, the volume of the patient's left upper lung mass decreased from 7.1 cm × 5.7 cm to 2.8 cm x 3.3 cm. Conclusion: The combination of surgical resection and duvacizumab drug therapy demonstrated clinical efficacy in patients with PSC and holds promise as a potential treatment option for patients suffering from PSC. |
|
| Keywords: Pulmonary sarcomatoid carcinoma, neoplasm metastasis, computed tomography, surgical resection, durvalumab. |
|
|
Full-Text [PDF 1010 kb]
(468 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. Guo H, Li B, Diao L, et al. (2021) An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC). Oncoimmunology, 10(1): 1947665. [ DOI:10.1080/2162402X.2021.1947665] [ PMID] [ ] 2. Yendamuri S, Caty L, Pine M, et al. (2012) Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery, 152(3): 397-402. [ DOI:10.1016/j.surg.2012.05.007] [ PMID] 3. Schrock AB, Li SD, Frampton GM, et al. (2017) Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling. Journal of Thoracic Oncology: Official publication of the International Association for the Study of Lung Cancer, 12(6): 932-942. [ DOI:10.1016/j.jtho.2017.03.005] [ PMID] 4. Pécuchet N, Vieira T, Rabbe N, et al. (2017) Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities. Annals of Oncology: Official journal of the European Society for Medical Oncology, 28(7): 1597-1604. [ DOI:10.1093/annonc/mdx162] [ PMID] 5. Maneenil K, Xue Z, Liu M, et al. (2018) Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients. Clinical Lung Cancer, 19(3): e323-e333. [ DOI:10.1016/j.cllc.2017.12.008] [ PMID] 6. Bae HM, Min HS, Lee SH, et al. (2007) Palliative chemotherapy for pulmonary pleomorphic carcinoma. (Amsterdam, Netherlands) Lung Cancer, 58(1): 112-115. [ DOI:10.1016/j.lungcan.2007.05.006] [ PMID] 7. Lee J, Jung HA, Kim Y, et al. (2018) Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. (Amsterdam, Netherlands) Lung Cancer, 122: 160-164. [ DOI:10.1016/j.lungcan.2018.06.009] [ PMID] 8. Hegde PS and Chen DS (2020) Top 10 Challenges in Cancer Immunotherapy. Immunity, 52(1): 17-35. [ DOI:10.1016/j.immuni.2019.12.011] [ PMID] 9. O'Donnell JS, Teng MWL, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy. Nature reviews. Clinical Oncology, 16(3): 151-167. [ DOI:10.1038/s41571-018-0142-8] [ PMID] 10. Liu X, Wang F, Xu C, et al. (2021) Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma. Oncogene, 40(4): 821-832. [ DOI:10.1038/s41388-020-01573-9] [ PMID] 11. Vieira T, Antoine M, Hamard C, et al. (2016). Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. (Amsterdam, Netherlands) Lung Cancer, 98: 51-58. [ DOI:10.1016/j.lungcan.2016.05.013] [ PMID] 12. Antonia SJ, Villegas, A, Daniel D, et al., PACIFIC Investigators (2017). Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 377(20): 1919-1929. 13. Paz-Ares L, Dvorkin M, Chen Y, et al., CASPIAN investigators (2019). Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. (London, England) Lancet, 394(10212): 1929-1939. 14. Antonia S, Goldberg SB, Balmanoukian A, et al. (2016) Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. The Lancet. Oncology, 17(3): 299-308. [ DOI:10.1016/S1470-2045(15)00544-6] 15. Travis WD, Brambilla E, Burke AP, et al. (2015) Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. Journal of thoracic oncology: Official publication of the International Association for the Study of Lung Cancer, 10(9): 1240-1242. [ DOI:10.1097/JTO.0000000000000663] [ PMID] 16. Thomas VT, Hinson S, Konduri K (2012) Epithelial-mesenchymal transition in pulmonary carcinosarcoma: case report and literature review. Therapeutic Advances in Medical Oncology, 4(1): 31-37. [ DOI:10.1177/1758834011421949] [ PMID] [ ] 17. Chang YL, Wu CT, Shih JY, Lee YC (2011) EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. Annals of Surgical Oncology, 18(10): 2952-2960. [ DOI:10.1245/s10434-011-1621-7] [ PMID] 18. Berg KB and Churg A (2017) GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung. The American Journal of Surgical Pathology, 41(9): 1221-1225. [ DOI:10.1097/PAS.0000000000000825] [ PMID] 19. Husain AN, Colby, TV, Ordóñez NG, et al. (2018) Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Archives of Pathology & Laboratory Medicine, 142(1): 89-108. [ DOI:10.5858/arpa.2017-0124-RA] [ PMID] 20. Lin Y, Yang H, Cai Q, et al. (2016) Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma. American Journal of Clinical Oncology, 39(3): 215-222. [ DOI:10.1097/COC.0000000000000101] [ PMID] 21. Zeng Q, Li J, Sun N, et al. (2021) Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma. Translational Lung cancer Research, 10(1): 18-31. [ DOI:10.21037/tlcr-20-960] [ PMID] [ ] 22. Chen M, Yang Q, Xu Z, et al. (2021) Survival analysis and prediction model for pulmonary sarcomatoid carcinoma based on SEER database. Frontiers in Oncology, 11: 630885. [ DOI:10.3389/fonc.2021.630885] [ PMID] [ ] 23. Sun L, Dai J, Chen Y, et al. (2020) Pulmonary sarcomatoid carcinoma: Experience from SEER database and Shanghai pulmonary Hospital. The Annals of Thoracic Surgery, 110(2): 406-413. [ DOI:10.1016/j.athoracsur.2020.02.071] [ PMID] 24. Özkan B, Erdoğdu E, Duman S, et al. (2021) Prognostic factors in patients undergoing pulmonary resection for sarcomatoid carcinomas of the lung. Balkan Medical Journal, 38(2): 104-110. [ DOI:10.4274/balkanmedj.galenos.2020.2020.7.45] [ PMID] [ ] 25. Park JS, Lee Y, Han J, et al. (2011) Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung. Oncology, 81(3-4): 206-213. [ DOI:10.1159/000333095] [ PMID] 26. Vieira T, Antoine M, Ruppert AM, et al. (2014) Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. (Amsterdam, Netherlands) Lung Cancer, 85(2): 276-281. [ DOI:10.1016/j.lungcan.2014.06.004] [ PMID] 27. Babacan NA, Pina IB, Signorelli D, et al. (2020) Relationship between programmed death receptor-ligand 1 expression and response to checkpoint inhibitor immunotherapy in pulmonary sarcomatoid carcinoma: A pooled analysis. Clinical Lung Cancer, 21(5): e456-e463. [ DOI:10.1016/j.cllc.2020.02.022] [ PMID] 28. Zhang L, Lin W, Yang Z, et al. (2022) Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art. Journal of Oncology, 2022: 8541157. [ DOI:10.1155/2022/8541157] [ PMID] [ ] 29. Qin Z, Huang B, Yu G, et al. (2019) Gingival metastasis of a mediastina pulmonary sarcomatoid carcinoma: a case report. Journal of Cardiothoracic Surgery, 14(1): 161. [ DOI:10.1186/s13019-019-0991-y] [ PMID] [ ] 30. Nishizawa Y, Kobayashi A, Saito N, et al. (2012). Surgical management of small bowel metastases from primary carcinoma of the lung. Surgery Today, 42(3): 233-237. [ DOI:10.1007/s00595-011-0005-8] [ PMID] 31. Kim MS, Kook EH, Ahn SH, et al. (2009) Gastrointestinal metastasis of lung cancer with special emphasis on a long-term survivor after operation. Journal of Cancer Research and Clinical Oncology, 135(2): 297-301. [ DOI:10.1007/s00432-008-0424-0] [ PMID] 32. Xie X, Tu N, Wang Q, et al. (2020) 18 F-FDG PET/CT imaging of small intestinal metastasis from pulmonary sarcomatoid carcinoma: Brief report and review of the literature. Thoracic Cancer, 11(8): 2325-2330. [ DOI:10.1111/1759-7714.13468] [ PMID] [ ] 33. Taira N, Kawabata T, Gabe A, et al. (2017) Analysis of gastrointestinal metastasis of primary lung cancer: Clinical characteristics and prognosis. Oncology Letters, 14(2): 2399-2404. [ DOI:10.3892/ol.2017.6382] [ PMID] [ ] 34. Hu Y, Feit N, Huang Y, et al. (2018) Gastrointestinal metastasis of primary lung cancer: An analysis of 366 cases. Oncology Letters, 15(6): 9766-9776. [ DOI:10.3892/ol.2018.8575] [ PMID] [ ] 35. Chen CH, Chen WM, Tung SY, et al. (2015) Gastrointestinal metastasis from primary sarcomatoid carcinoma of the lung: a case report and review of the literature. World Journal of Surgical Oncology, 13: 174. [ DOI:10.1186/s12957-015-0599-1] [ PMID] [ ] 36. Romano A, Grassia M, Rossetti AR, et al. (2015) Sarcomatoid carcinoma of the lung: A rare case of three small intestinal intussusceptions and literature review [J]. Int J Surg Case Rep, 13: 48-50. [ DOI:10.1016/j.ijscr.2015.05.025] [ PMID] [ ] 37. Rossi G, Marchioni A, Romagnani E, et al. (2007) Primary lung cancer presenting with gastrointestinal tract involvement: clinicopathologic and immunohistochemical features in a series of 18 consecutive cases. Journal of thoracic oncology: Official publication of the International Association for the Study of Lung Cancer, 2(2): 115-120.
https://doi.org/10.1097/01243894-200702000-00004 [ DOI:10.1016/S1556-0864(15)30037-X] [ PMID] 38. Xiao C, Yang X, Hao J, et al. (2021). Clinicopathological features and prognostic analysis of metastatic pulmonary sarcomatoid carcinoma: a SEER analysis. Journal of Thoracic Disease, 13(2): 893-905. [ DOI:10.21037/jtd-20-2826] [ PMID] [ ] 39. Gao C, Zou Q, Liu H (2022) Pulmonary Sarcomatoid Carcinoma With Epiglottis and Ileum Metastasis Detected by 18F-FDG PET/CT. Clinical Nuclear Medicine, 47(3): 231-233. [ DOI:10.1097/RLU.0000000000003936] [ PMID] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
|
